Just to keep living, and without any special activities, we already need lots of energy: about 30 kcal (126 kJ) per kg body weight per day. Apart from this fuel, which we burn, we need "building blocks and tools" for our body and we have to get rid of unnecessary or toxic molecules. So, we cannot live without massive exchange with our environment. Exchange entails risks. Our gastrointestinal tract is tasked with performing the required exchange while minimizing concomitant risks.
Simply put, the strategy is the following: Keep complex stuff outside. Break it down to "generally accepted building blocks". Import only those secure building blocks. Alas, we have to make many exceptions. For one, we depend on some highly complex molecules that we have to import for lack of the ability to synthesize them ourselves, e. g., vitamin B12. We need special tools for that, like the special services required to move old master paintings across geographical and political barriers. In addition, to guard our borders, we need to give our defense system an idea of the dangers outside, as well as a chance to learn how to tell them apart from the normal harmless antigens that need to be tolerated. To do that, we open channels to take in small random samples of complex structures from outside. Although we monitor these samples closely, the process is sometimes used against us to slip in dangerous material.
EVOLUTIONARY ASPECTS
What is healthy food? This question touches everybody and is able to raise high emotions. Food fads come and go, their respective supporters fighting each other with gusto. The habit of consuming high-fat meat or meat products like briny ham or sausages on a daily basis, common in affluent parts of the world, certainly isn't healthy. But neither is the opposite, a purely vegetarian or vegan diet, for lack of vitamin B12 and usable iron, which need to be substituted.
In this debate, it is helpful to keep an eye on our evolutionary origins. While modern Homo sapiens lives all over the world, this is a fairly recent development. For all we know from analyses of mitochondrial DNA and Y chromosomes, all humans originating from Europe, Asia, Australia and the Americas are descendants of a fairly small group of people who emigrated out of Africa and the Middle East between 70,000 and 60,000 years ago. In evolutionary terms, this time is too short to accommodate a great deal of genetic adaptation. In other words, to a large extent we are still the product of selective forces active in Paleolithic Africa. We are optimized to function under those conditions. While it is impossible to reconstruct the menu of that time, a few aspects seem very likely. Most of the time, food was in short supply. Selective pressure favored people with "thrifty alleles" who were able to form reserves, fat deposits, efficiently during occasional times of plenty to help them survive long periods of penury. Meat of wild game was desirable, but hard to obtain. For the majority of their nutrition, people relied on plants, meaning roots, tubers, nuts and in wetter places, fruits. Carbohydrates generally made a smaller contribution to the diet. Most of the time, these were of the complex type, as mixtures of starch and fiber. "Sweet" simple sugars like glucose of fructose were rarely available, restricted, e. g., to berries in fall. Milk and cereals, products of the Neolithic (agricultural) revolution starting 10,000 years ago, were absent. Average plant:animal subsistence ratio has been estimated around 65:35. Compared to our average Western diet, food intake was thus likely high in protein and fibers, moderate in fat and low in carbohydrates. To feed oneself required lots of movement and hard manual labor. In the African sun, it was important to conserve water. For osmotic reasons, this implied conserving salt, which was sparse except at the coast.
Archeological evidence tells us that the agricultural revolution had a strongly negative impact on human health. People suffered from malnutrition, were smaller, had bad teeth and had a lower life expectancy.
These considerations are intended to illustrate conditions of importance for our nutrition and health. Expressly, I don't want to imply that we should eat a Paleolithic diet today, although I believe that would be healthy. Firstly, for the large majority of us, this is simply impossible. Paleolithic meat was qualitatively different from today's meat: wild game contains far less fat than our fatstock. Secondly, in view of the calories required, grains, corn and rice are irreplaceable. In a world with seven and a half billion people, we have to behave differently than our ancestors, who numbered a few hundred thousands at most. Intensive mass-animal farming on the scale required to provide meat frequently for so many people seems ethically impossible. We urgently need to develop a form of nutrition that integrates health and ethical concerns and is fair and economically feasible on a global level. But this is not my topic.
Here, I concern myself only with aspects of nutrition relevant for the health of the individual. For practical reasons, I assume the present situation in affluent countries, where meat and other animal source foods are affordable and available in every grocery shop.
OVEREATING
Today, the thrifty Paleolithic genetic endowment is less than optimal for people living in conditions of ample food supply. The imbalance is accentuated by a pervasive lack of physical activity and exercise. Concerning the availability of food, we live in a continuing feast. If we fail to make a stand against the constant lure of food, we accumulate fat deposits until they start to be toxic. Remember that toxicity is a function of the dose. There is accumulating evidence that the moderate increase in free fatty acid (FFA) concentrations seen in obesity causes metabolic problems at two levels: insulin-sensitive target tissues and insulinproducing β-cells.
Insulin resistance: Target tissues
Free fatty acids that are not "burned" accumulate in the cytosol of skeletal muscle and adipose tissue and are reincorporated into triacylglycerols. In this process, levels of the intermediate diacylglycerol increase, too. Diacylglycerol is a second messenger that activates protein kinase C (PKC). Active PKC and other serine/threonine kinases phosphorylate insulin receptor substrate 1(IRS-1) at inhibitory sites, reducing its ability to transmit the insulin signal into the muscle cell (to avoid confusion: in contrast, activated insulin receptor phosphorylates IRS-1 on tyrosines, which is required for signal transduction). In healthy individuals, muscle and fat cells respond to insulin by inserting more units of glucose transporter 4 (GLUT4, K M 5mM) into the plasma membrane. If insulin signal transduction is compromised by the fatty acid effect, lower amounts of glucose can be transported into these huge tissues and blood glucose remains higher. Of course, all of our cells consume glucose all the time. Yet, they take up glucose via transporters GLUT1 and GLUT3 (K M 1mM), which are running at capacity at normal glucose levels (4.5mM= 80 mg/dl) anyway. Liver cells and pancreatic βcells take up glucose via GLUT2 (K M 15-20mM). The higher K M means, more glucose is transported into these cells at higher blood glucose levels. In the liver, surplus glucose is metabolized to fatty acids, increasing the problem. Recall that GLUT1, GLUT3 and GLUT2 do not respond to insulin.
In an independent mechanism, saturated fatty acids like lauric acid (C12) or palmitic acid (C16) have been shown to act as partial agonists on TLR4 (the LPS receptor) and TLR2. Via this mechanism, increased plasma levels of FFA activate inflammatory pathways that also lead to reduced insulin-sensitivity of liver, muscle and adipose tissue. For example, IL-6 or TNFα released from adipose tissue induce SOCS (suppressor of cytokine signaling) proteins in liver cells. SOCS proteins bind and mask phosphorylated tyrosines on IRS-1, interfering with signal transduction and inducing proteasomal degradation of IRS-1.
Regular aerobic exercise enhances expression of enzymes required for fatty acid metabolism and increases the mass of mitochondria. That way, regular exercise leads to more efficient metabolism of fatty acids, and thus to an increase in insulin sensitivity.
Insulin resistance: Pancreatic β-cells
With target tissues less responsive to insulin, plasma glucose concentrations are slightly increased. Glucose enters pancreatic β-cells via glucose transporter 2 (GLUT2, K M 15-20 mM) in proportion to its blood concentration, stimulating the production of ATP. ATP binds to an ATP-sensitive K + channel: the higher the ATP concentration, the lower the channel's open probability. The K + channel contributes to membrane resting potential. Closing the channel elevates the membrane potential to the threshold of voltage-dependent Ca 2+ channels. Influx of Ca 2+ then leads to exocytosis of insulin-filled vesicles.
Pharmacology cross reference:
The ATP-sensitive K + channel (subunit ABCC8 or SUR1, sulfonyl urea receptor 1) is the target for sulfonylureas. Binding of sulfonylureas promotes closure of the channel, thereby enhancing insulin secretion.
Increased blood glucose concentrations (which in healthy individuals range between 4 and 8 mM, or between 72 and 144 mg/dl) thus stimulate insulin synthesis and release. Beta cells have an enormous capacity to synthesize insulin; up to 50% of the total protein synthesized in the pancreas may be proinsulin. Yet over time, constant overproduction of proinsulin puts the endoplasmic reticulum under stress, and unfolded or misfolded proteins accumulate. This problem not only concerns insulin, but also a protein hormone called IAPP (islet amyloid polypeptide) or amylin, which is co-regulated as well as co-expressed and secreted with insulin. There are standard operating procedures for any cells in this situation: ER stress activates the unfolded protein response (UPR), which consists of several steps. First, general protein synthesis is inhibited. This reduces the output of insulin. Second, chaperone synthesis specifically is increased to aid in the folding of newly synthesized protein. Third, misfolded proteins are exported from the ER to the cytosol and broken down in the proteasome. If all this doesn't bring relief, eventually, programmed cells death is triggered. In addition, in this particular case, conglomerates of misfolded IAPP show a tendency for prion-like proliferation and are particularly toxic. Over time, this process reduces pancreatic β-cell capacity, leading from insulin resistance to overt diabetes mellitus type 2.
Again, additional mechanisms contribute. FFA induce production of IL-1β, IL-6 and IL-8 in human islets. IL-1β expression is enhanced by an autostimulatory process, and the production of insulin deteriorates under the influence of IL-1β. Blockade of IL-1β function with the IL-1 receptor antagonist anakinra improved β-cell function and reduced levels of glycated hemoglobin.
While we don't yet understand the exact chain of causation, the term "metabolic syndrome" was coined to describe the total of observed changes. Insulin resistance, via diabetes mellitus type 2, causes a broad spectrum of morbidity, including atherosclerosis, coronary artery disease, stroke, diabetic nephropathy, retinopathy and polyneuropathy.
These problems do not affect all of us to the same extent. In the genetic lottery, some of us have drawn more, others fewer thrifty alleles. In one study, an individual with 104 out of 194 thrifty gene variants was on average 11 kg heavier than someone with only 78.
What is a thrifty gene? One example: FTO gene and brown adipose tissue
Life is not fair: Some people can eat a lot without adding weight, most people can't. Some people never seem to be cold; relaxedly, they sit around short-sleeved while others pull up the zippers of their jackets. So, maybe, some people just burn more food to produce heat? Until a few years ago, it was thought that brown adipose tissue (BAT) only existed in babies. Usually, fat is white, but patches of specialized fat cells containing a high load of mitochondria appear beige or brown. These cells use their mitochondria to burn fat or glucose to produce heat. Normally, mitochondria use the energy of a proton gradient to produce ATP, like a mill would use the energy of a creek for grinding grain. If the miller uncoupled the cog wheels of his mill from the grindstone, the now faster turning wheels would produce only heat, not work. Similarly, by expression of uncoupling protein 1 (UCP1 or thermogenin), protons are diverted from driving ATP synthase (the grindstone) by being allowed to trickle back through the inner mitochondrial membrane. This way, beige or brown fat cells are able to uncouple fat burning from mitochondrial ATP production, burning a lot of fat for heat. The process is stimulated by a cooperation of sympathetic activation with thyroid hormone. Activation of β 3 -adrenergic receptors induces iodothyronine deiodinase type II, a selenoprotein converting thyroxine (T4) to the more active triiodothyronine (T3). T3 activates the thyroid hormone receptor, which sits at the promoter of the UCP1 gene.
Then, via the technique of 18 F-fluorodeoxyglucose PET-CT, it was recognized that beige or brown fat also existed in adults, in small patches in the anterior neck and in the thorax. Initially, it could only be identified in lean subjects or if the test subjects were exposed to cold. Over time, it was established that short-term exposure to cold (hours) increases BAT activity, long-term exposure (weeks) also expands BAT volume. With sufficiently harsh cold exposure, BAT can be demonstrated in almost everyone. Yet, lean people tend to have more BAT.
Independently from these developments, genome-wide association studies were carried out to identify genetic variants contributing to obesity. Repeatedly, a gene of unknown function, now designated fat mass and obesity associated (FTO) came out at the top. However, the mechanism by which certain allelic variants of this gene contributed to obesity remained unclear. Eventually, it was recognized as a DNA maintenance enzyme taking off methyl groups from thymidine, but that did not help to understand its relation to obesity.
Finally, in 2015, an unexpected model was proposed: the feature of the FTO gene contributing to obesity is not its encoded protein, but rather a binding site in intron 1 for a gene-regulatory protein which acts on genes further down the chromosome. Somewhere between exons 1 and 2 of the FTO gene on chromosome 16, a single nucleotide polymorphism (SNP rs1421085) means some of us carry a C (let's call it "thrifty-C"), some of us carry a T ("thermo-T"). Of course, we have two of these chromosomes, so our genotype may be CC, CT or TT. To keep things simple, let's just consider CC and TT genotypes (CT might be somewhere in between). 1. You are a thermo-TT type? Then you are lucky, because you burn off fat more easily. A complex chain of events makes that happen. A gene-regulatory protein, ARID5B, binds to the DNA at the spot of thermo-T. It acts as repressor, inhibiting transcription of two genes further down the DNA, IRX3 and IRX5. These two genes encode proteins that are gene repressors in their own right, acting as switches between brown and white in the development of new fat cells. Thermo-T represses these repressors, allowing the development of higher amounts of BAT. If you are TT, you burn off a higher proportion of ingested calories for heat. Maybe you are the short-sleeved-in-the-cold-type! BUT if you had lived in the Paleolithic, you would have been less lucky. Constantly burning off more calories, you might have been among the first who starved in a prolonged famine. 2. You are a thrifty-CC type? Then you are excellently equipped for a Paleolithic environment. Thrifty-C prevents binding of the ARID5B repressor protein. Down the line, IRX3 and IRX5 are expressed more strongly, preventing the browning program in new adipocytes. Lots of white adipose tissue is formed, allowing you to build fat stores in good times. Better chances to survive the next famine! So, now we understand one thrifty gene. But there are more than one hundred of them, and each one contributes only a small fraction to the overall variance in body mass index observed. Depending on the stack of alleles we got from our parents in the grand genetic lottery, we are more energy-thrifty or more short-sleeved, and as yet there is nothing we can do about that. Those enviable individuals who missed out on thrifty alleles have no problem staying slim and trim; for the majority of us, maintaining weight requires a conscious effort.
An additional factor promoting overweight, which may be regarded as part of the Paleolithic program, is the fact that foods rich in sugar and fats (Yummy! Chocolate!) trigger the same reward pathways as certain drugs like cocaine. With limited availability of calorie-dense foods, this behavior-guiding mechanism was useful in times past; today, it is a problem.
The contribution of our microbiota
A second factor causing inter-individual differences is the specific community of bacteria in our digestive tract. In their entirety, these have been known as gut flora, but today are mostly referred to as microbiota. Clearly, these differ between lean and obese people. Less clear is what is cause and what is effect. The human gut is inhabited by a complex community of bacteria and archaea distributed over at least 1000 species overall. Each of us carries more than 10 14 cells, from at least 160 species. About 60 species have been found in more than 90% of Europeans. The ratio of two phyla, Firmicutes (e. g., Clostridium, Lactobacillus) and Bacteroidetes (e. g., Bacteroides, Xylanibacter) has been reported to correlate with obesity: Firmicutes dominate in obese, Bacteroidetes in lean individuals. The composition of an individual's microbiota is shaped by several factors. The primary factor is an individual's diet.
Hypotheses in this field are derived from experiments based on germ-free mice. Germ-free mice are born and reared without exposure to any live microbes. These mice can subsequently be colonized with selected microbial species or "fecal transplants" from mice or humans to test whether this colonization leads to measurable physiological of pathological effects. Germ-free mice are protected from obesity and metabolic syndrome, but adiposity is substantially increased when they are colonized with conventional microbiota. Mice colonized with microbiota from obese mice or obese humans, containing, e. g., the archaeon Methanobrevibacter smithii, gain more weight than mice colonized from lean subjects. How is this possible? Microbiota may promote adiposity in three ways:
1. By increased energy harvest from food. In principle, we are familiar with this concept: think of ruminating cattle. In principle, a cow is no more able to digest grass than we are, but it gets help from bacteria and archaea in its specialized digestive tract. Non-digestible carbohydrate components of grass, like cellulose ore xylans, are fermented in its compartmentalized stomach with the help of microbes, enabling the cow to use a large part of the energy contained. In mice or humans, this process is far less efficient, as most microbes inhabit the colon, which is located downstream of the small intestines where energy-absorption takes place. Yet, short-chain fatty acids (acetate, propionate, butyrate) produced by fermentation of otherwise indigestible carbohydrates may be taken up even in the colon, enhancing energy extraction from food. Yet, fermenting indigestible carbohydrate chains is not necessarily synonymous with adding weight. The fermenting process may also promote species that have a positive effect on metabolism via other mechanisms (see next paragraph) or outcompete harmful species.
2. By directly adjusting physiological parameters of the host organism. Apart from being taken up as a form of energy, certain short-chain fatty acids activate G protein-coupled receptors Gpr41 and Gpr43. Activation of Gpr41 results in changes in secretion of PYY (described below), activation of Gpr41 in changes in secretion of glucagon-like peptide 1 by intestinal L cells. A second example: gut epithelial cells of germ-free mice produce considerable amounts of fasting-induced adipose factor (fiaf or ANGPTL4). Fiaf, a glycoprotein, inhibits lipoprotein lipase (LPL), which is responsible for the uptake of fatty acids from chylomicrons and VLDL into adipose tissue. More fiaf therefore means less adiposity. Colonization of germ-free mice with conventional microbiota suppresses expression of fiaf in intestinal cells, causing mice to grow fatter. Yet, if germ-free mice are specifically colonized with Lactobacillus paracasei, fiaf levels remain elevated.
3. By instigating inflammatory reactivity in the host. Interactions between genetic host factors, diet and microbiota may increase gut permeability. With higher permeability, traces of microbiota-derived lipopolysaccharides and microbial DNA reach the liver via the portal vein, activating Toll-like receptors 4 and 9, respectively. This pro-inflammatory effect may promote visceral adiposity, non-alcoholic fatty liver disease and insulin resistance.
To what extent these findings apply to humans is being investigated. Long-known phenomena, such as the healthful effects of dietary fiber, may be understood by their impact on the microbiota. For example, in patients with diabetes mellitus type 2, a defined fiber-rich diet promoted microbiota species that caused increased glucagon-like peptide production and decreased HbA1c levels. In any case, when thinking about our propensity to accumulate weight, we have to consider not only our genetic programming, but also our microbiota and the microbiota-selecting properties of our diet.
While the time for evolutionary adaptation was short since leaving Africa, changes in selective pressure have left their mark in some populations. We have indications that at the time food shortage reversed into its opposite for the first time, populations suffered massive bouts of morbidity. In parts of Europe, this started during Roman times, when progress in agriculture and well-organized transport systems led to massive improvements in the average food situation. Probably, many people died from diabetes mellitus and related conditions at a young age. In these societies, counter selection happened against thrifty alleles. Today, problems due to obesity and diabetes are most pronounced in those populations who encounter caloric plenty for the first time.
In principle, losing weight is straightforward: take in fewer calories than you spend. Yet, we are hardwired to hate the condition of negative energy balance. Soon, energy saving mechanisms kick in that make us passive, grumpy, cold, craving for food and ready to shamelessly lie to ourselves. Therefore, few people are able to lose weight by just eating less. Successfully losing weight usually requires sweeping adaptations in our daily behavioral and social routines, including diet and drinking habits as well as the level of our physical activity. Aerobic exercise counters the body's attempts to enter energy conservation mode.
Rather for our society's obsession with appearance than due to real health concerns, losing weight is high on our list of priorities. Yet, far too frequently, people are enticed to pay good money for bad advice or products of questionable value. In the following, I therefore provide a (free!) evidence-based list of recommendations on how to lose weight in a sustainable way. Many aspects are explained in more detail further down these lecture notes.
How to lose weight sustainably
Above all, body weight is a result of energy balance. Losing weight simply means taking in fewer calories than you spend. There's no diet, no trick, no magic around that.
The input side:
1. Resolve to eat a little less than you need for a long time. Most people are ill-served by rigorous short-term diets. They punish themselves for a few weeks, longing for the day it's finally over and setting themselves up to yo-yo back.
2. Hold yourself accountable. Make a long-term plan. One pound (0.5 kg) a month is reasonable.
3. Accept being a little hungry part of the day. As long as you take up calories from a meal, insulin predominates and parts of these calories are converted to fat. Once the process reverses, glucagon predominates, and you get hungry again. Hunger is the signal to Palaeolithic WoMan to go foraging again: first the exercise, then the next meal. As long as you are hungry, you burn fat. People who claim you can lose weight without being hungry usually are after your money. 7. Serve smaller portions, use smaller plates to counter the portion-size effect.
8. Eat unprocessed foods: fruit, vegetables, legumes, salads, lean meat, fish. Processed foods tend to be more energy-dense, i.e., contain too much fat and simple sugars. Plus, they frequently contain too much salt, trans-fats and other ingredients you are not aware of.
9. Eat protein-rich foods. By stimulating PYY, a protein-rich meal helps to delay the return of hunger compared to isocaloric alternatives. Protein-rich foods include lean meat, fish, and eggs. Vegetarians can resort to tofu, seeds (pumpkin, sunflower) and nuts.
10. Prefer low glycemic index foods. This matches well with the previous two points: unprocessed and protein rich foods tend to have a lower glycemic index. Cut down on sweets, sugar, chocolate, pastries. For breakfast, replace processed cereals or white bread with whole-grain muesli containing fresh fruits.
The spending side:
11. Increase your daily energy spending: walk or cycle to work instead of driving. Take the stairs, not the elevator. Use a pedometer and try to increase your average daily step count.
12. Build up a routine to have some form, any form of aerobic exercise two, better three times a week for at least 30 minutes. This increases metabolism for many hours. Vigorous walking, jogging, cycling, swimming, cross-country-skiing, dancing-anything will do.
13. Keep room temperature and clothing on the cool side. Let your body spend more energy on its own heating via adaptive thermogenesis by brown adipose tissue and muscle.
Intuitively, our idea of losing weight looks something like this: for a certain period, we eat less until we reach our weight goal. Then, we return to eating "normally", meaning about as much as before. Unfortunately, this concept is mistaken, for two reasons:
1. Our body's energy expenditure is a function of its mass. If you have trouble believing this, try hauling around a twenty pound backpack for a few days. After shedding pounds successfully, our body requires fewer calories. Example: A 22 year old female, 5' 5'', 154 lbs (BMI 25.7), decides to lose weight. After an arduous struggle and many setbacks, she loses 22 pounds. Her "new"132 lbs-body requires only 2170 kcal per day, while her "old" 154 lbs-body was able to consume 2340 kcal without adding weight. From this alone, she needs to consume 170 kcal less than before to prevent regaining weight.
2. Yet, actual daily caloric allowance is even lower. Our body "memorizes" our elevated initial weight and tries to claw its way back up. In persons who had lost more than 20 pounds and who succeeded in keeping most of it off for at least a year it was found that their body still interpreted the lower weight as something of a deficit: satiety hormones leptin and PYY stayed reduced, hunger hormone ghrelin stayed high and the test persons reported an elevated sense of hunger. Careful measurements showed that people had lower total energy expenditure under these conditions than comparable control persons who had not lost weight. In our example, at 132 lbs the young woman's body would consume 2170 kcal only if she had never exceeded that weight. Yet, her "post-154 lbs" 132 lbs-body remains in energy conservation mode, consuming less. So far, this additional reduction in energy expenditure has been quantified in few probands, and individual values varied widely. Therefore, it is not possible to pinpoint any exact number in our example, but it seems reasonable to assume a further reduction between 100 and 400 kcal. For how long? Unfortunately, we do not know that yet. For the few individuals assessed in this regard, the energy-saving mode was still being active six years later.
Altogether, this puts the young woman's actual steady-state daily caloric requirement somewhere between 1770 and 2070. In other words: if she wants to keep those pounds off, she needs to consume 270-570 kcal or about half a meal less than what she would consider "normal", in the face of an increased sensation of hunger. Now we understand why it's so difficult to lose weight and keep it off. In conclusion, it is a lot easier to prevent overweight than to correct it. Prevention of weight gain, as well as prevention of smoking, are mundane yet highly effective medical goals.
HIGH INTAKE OF SALT
Our genetic makeup prepares us better to cope with a lack of salt than with a glut of salt, like it prepares us better for a restriction in calories than for an abundance of them. While we have an extremely efficient sodium saving system in the form of the aldosterone system, our mechanisms to get rid of superfluous sodium are less refined, as sodium overflow did not exist during evolution of modern Homo sapiens. While evolution primed us to crave salt, we now have cheap salt within reach all the time. Together, these two conditions cause general overconsumption of sodium. With our unsophisticated elimination system, more sodium leads to an increase in fluid volume for osmotic reasons. At the margin, increased fluid volume in the closed system of our extracellular space results in increased pressure. Only with this elevation in blood pressure, we are able to excrete more sodium, as renal excretion is proportional to tubular flow rate (pressure natriuresis). Thus, our high intake of salt promotes hypertension. The DASH eating plan (Dietary Approaches to Stop Hypertension) addresses this issue and generally constitutes a useful guide to healthy nutrition.
MALNUTRITION
In painful contrast to the opulence experienced in part of the world (about 400 million suffer from diabetes mellitus type 2), hunger is one of the most pervasive medical problems. About 800 million people are malnourished. According to the Food and Agriculture Organization of the United Nations (FAO), every five seconds, a child starves to death.
A large part of this hunger is man-made. This is true for its increase by climate change, but also for the economic system we use to produce and distribute food.
[Two examples:
1. For budgeting reasons, both the French wheat farmer and the owner of a bakery chain in Austria have an interest in securing their wheat price six months ahead. In principle, they could mutually agree to a shipment at a certain point in time at a certain price. A contract of this type is termed commodity future.
In real life, neither farmer nor baker has the time to look for a partner. They rely on an intermediary. What actually happens looks more like this: the farmer pays a certain amount to a broker for the right to sell his wheat until a certain date at a predetermined price. We call that a put option. Likewise, the bakery owner pays the broker for the right to buy an amount of wheat until a certain date at a predetermined price: he buys a call option. An option is a contract involving the trade of a right. The paying partner acquires the right, the partner who gets the money incurs the obligation to fulfill the underlying transaction. The price of the option is a kind of insurance premium to secure a wheat price in the future. As the term option implies, the holder has no obligation to do the deal: if the market price of wheat at harvest is higher than the option strike price, the farmer is free to sell to the highest bidder. Unexercised options expire worthlessly, with the seller keeping the premium. Rights and obligations may be traded, leading to an options exchange. Hedge funds, banks, insurance companies with not the least direct interest in wheat buy and sell these options if they expect to make a profit. A second type of exchange-tradable commodity forward transactions is futures. In contrast to options, a futures contract obligates both parties to fulfill the deal.
Most participants in commodity options and futures markets are neither producers nor end users. They are only interested in profit margins and will capitalize on any opportunity to raise them. For example, if the Russian government bans wheat exports in response to a harvest-threatening drought, well-connected market participants will notice this fact a little earlier than the Austrian baker or other end users. In the relatively small group of market participants from large finance companies, there is no need for explicit arrangements, it's clear to everybody how to profit from the situation: from this moment on, there will be considerable restraint regarding commitments to ship wheat. If an end user insists on securing a shipment, he has to pay up. In other words, the call option premium goes up in addition to an increase in the strike price. While a tightening of the wheat market is an entirely negative event from the perspective of food supply, it allows some market participants to make large profits. The expected crop shortfall in Russia by itself would have made wheat more expensive, but the options trade additionally amplifies price increases. Until expiration of the call options he owns, the Austrian baker is protected from price increases, but the next call he buys will be considerably more expensive. When the price of bread goes up again, we consumers are irritated. Yet, for the more than 1.2 billion people who have to survive on less than €1 per day, the resulting price increases quickly become life-threating.
Is there any solution? It might be beneficial to restrict access to food commodity exchanges. Legal regulation might grant access to food commodity trading for producers, end users, and, as far as necessary, brokers, but prevent speculation in agricultural commodities detached from actual use. Regulations along these lines have not even been attempted so far and would probably have to be enacted against determined lobbying efforts by the financial services industry.
2. Another factor tending to raise food prices is the production of biofuel. E5 designates gasoline containing 5% ethanol, which is produced by fermenting wheat, corn or sugar beets. While it is possible to use, e. g., sugar cane from wetlands instead, preventing direct competition for agricultural land, today's actual share of wheat and corn in global biofuel production is high.
Has any of this any relation to medicine? If people die from it unnecessarily: yes!]
As a result of poverty, people survive on very restricted diets, essentially maize or rice. While this may satisfy caloric requirements, it fails to supply many essential nutrients, over time inescapably leading to illness and, potentially, death.
Given a reliable source of carbohydrates, our organism is able to produce energy. It is also able to resynthesize other complex carbohydrates and most lipids. The problems start with the proteins. Of the twenty amino acids, we lack the ability to synthesize eight -children even more--, making it necessary to take them up from outside. In maize or rice, several of these are present in inadequate amounts. Essentially, our proteins are chains of amino acids: one missing link is enough to disrupt the chain. In the extremely restricted diets of the poor in the developing world, the limiting amino acid is usually lysine, followed by tryptophan.
Kwashiorkor
As soon as one amino acid becomes limiting, the organism cannot produce enough protein molecules. This becomes visible first for those proteins that have to be produced in high copy numbers: muscle proteins and albumin. Albumin is necessary to maintain oncotic pressure and a lack of albumin results in pedal edema and pot belly by ascites. In a seeming paradox, the liver tends to be enlarged by fatty infiltrates, as lipids fail to be shipped to the periphery for lack of apoproteins required to assemble VLDL. Thinning hair of reduced pigmentation and dermatitis are further typical signs. Affected children and adults are apathetic and highly susceptible to infections, as an effective immune response depends on the production of antibodies and cells. The term "Kwashiorkor" originates from the Ghanese Ga language, meaning "the sickness the baby gets when the new baby comes". As the older child is weaned from the mother's breast, the balanced amino acid composition of breast milk is replaced by the lopsided one of high-starch crops like maize. Of course, these restricted diets invariably entail additional nutritional deficiencies, regarding, e. g., iron, vitamin B12 and niacin, and tend to contain high levels of contaminating aflatoxin, all of which contribute to the disease.
CENTRAL REGULATION OF APPETITE
Appetite and eating behavior are regulated in the hypothalamus, with much of the activity concentrated in the arcuate nucleus. Here, information on energy supply converges via afferent neuronal and hormonal (e. g., leptin, ghrelin) signals.
Portion size effect
Food intake increases with portion size. Give the average person a large plate with more than she/he can eat, and she will eat a given amount. Give the same person an even larger portion, and she will eat more than the first time around. Although we are far from understanding complex brain functions like this, the portion size effect is probably part of the program to increase reserves during times of plenty.
Practical implications: when trying to lose or to maintain weight, use smaller portions/plates. Avoid those bathtub-size popcorn bowls.
Leptin
Leptin (from the Greek word leptos=thin) acts as an input to the central nervous system reflecting the prevailing food situation. In response, the CNS reacts with meaningful adaptations of eating behavior, reproductive functions and bone metabolism (anorexia nervosa, for example, combines decreased leptin levels, amenorrhea and osteoporosis).
The signal protein leptin is almost exclusively secreted by adipocytes (an adipokine). Its long term plasma level is proportional to the size of an individual's fat storage. Around this level, leptin levels oscillate diurnally dependent on food intake, with a minimum at breakfast and a maximum late in the evening. In addition, changes in food situation cause temporary divergence. Leptin levels decrease following a few hungry days, and increase after a period of feasting. Leptin acts on numerous tissues, but its main target is thought to be the brain. Leptin is able to cross the blood brain barrier, affecting the autonomic nervous system via hypothalamic centers. Decreased leptin levels lead to a strong feeling of hunger, leptin levels in the normal range to satisfaction ("satiety") with increased willingness to be active and to spend energy. Further increases of leptin levels by obesity remain without significant additional effect. For some time, leptin was hoped to be the answer to the obesity epidemic. Indeed, a very small percentage of obese people have leptin deficiency. However, the overwhelming majority of obese individuals were found to be leptin resistant, much like type 2 diabetics are insulin resistant, meaning high leptin concentrations do not reduce their appetite.
"Hunger" is generated in the hypothalamus
The sensation of satiety is generated by a combination of signals. Central cooperation between leptin and insulin plays an important role. Both leptin and insulin stimulate "anorexigenic" (appetite-reducing) POMC-expressing neurons in the arcuate nucleus. These neurons release a POMC (pro-opiomelanocortin) cleavage product, α-MSH (α-melanocyte stimulating hormone), at their synapses. α-MSH stimulates certain melanocortin receptors (MC4R) on "satiety" neurons, resulting in increased metabolic rates and diminished food intake. About 4% of patients with severe early-onset obesity have mutations in melanocortin receptors. POMC neurons also synthesize CART (cocaine-amphetamine related transcript), which also promotes satiety and activity. Incidentally, POMC neurons are also stimulated by nicotine, explaining the lower average body mass index of smokers as well as their tendency to gain weight after quitting.
Pharmacology cross reference: For some time, drugs from the amphetamine family were broadly used as appetite suppressants. In Europe, this practice was discontinued when it became clear that their dependency-promoting properties and other unwanted effects could not be dissociated. Drugs from the amphetamine family work by increasing serotonin concentrations in the synaptic cleft. POMC neurons are activated via serotonin 5-HT 2C receptors. The simultaneous activation of 5-HT 2B receptor by some of these drugs, however, promoted fibrosis of heart valves and pulmonary artery wall, and repeatedly led to valve problems and pulmonary hypertension. The 5-HT 2C agonist lorcaserin is approved in the US, but not in the EU, to aid weight loss.
In contrast, leptin inhibits a second group of neurons in the arcuate nucleus that release Agouti-related peptide (AgRP) and neuropeptide Y (NPY). These counteract the POMCexpressing neurons. AgRP acts antagonistic at the MC4R. The AgRP "hunger neurons" promote hunger, food intake, and build-up of fat deposits while slowing the readiness for activity and thermogenesis in brown adipose tissue. Asimple, but impressive experiment to personally experience your AgRP neurons in full swing: don't eat anything for 24 hours and observe yourself: torpid, freezing, ill-humoured.
But then the reward: a good meal! In addition to leptin, the prospect of imminent food intake induces the CNS to slow the activity of AgRP neurons. The CNS is an organ to project the future: sitting in front of steamy plates, our satisfaction already starts to increase and hunger begins to fade; we do not have to suffer from nagging hunger until leptin and insulin finally rise after eating.
What is hunger? Hunger is an initially undirected feeling of displeasure generated by AgRP neurons. We try to avoid this unpleasant mental state and learn early in life which behaviors (food intake) silence the AgRP neurons. Babies and small children show their feeling of displeasure very directly. They can not help themselves yet, but have no difficulty triggering the necessary behavior in their parents.
Sensory influences (the steaming plate) reduce the activity of the AgRP, but a second phase of early attenuation is caused by signals from the intestine. This probably has the following background: if we were to eat until glucose, leptin, and insulin are high enough to shut down AgRP neurons, we would overshoot the target, as the gut at that point in time contains a large amount of food still awaiting absorption. So, early on, the gut reports an estimate about the amount of food that can be expected to be absorbed soon; and would you please be so kind to lift that hungry feeling right now? This happens on the one hand via afferent neurons of the autonomic nervous system, on the other hand via signal peptides such as PYY and GLP-1.
Peptide YY (PYY)
PYY is released by mucosal neuroendocrine L cells in the distal gut in response to intake of food. PYY levels increase within 15 minutes, long before nutrients have reached the L cells, and remain elevated for up to six hours. Comparing isocaloric meals high in either carbohydrates or protein or fat, respectively, meals high in protein lead to the highest plasma levels of PYY. In addition to peripheral effects, like reducing gastrointestinal motility and secretion, PYY promotes satiety. It specifically activates Y2-receptors on hypothalamic neurons, again resulting in activation of the anorectic POMC-expressing neurons in the arcuate nucleus. In addition to PYY, cholecystokinin chips in to promote postprandial satiety.
Practical implications:
A protein-rich meal helps to delay the return of hunger, making it easier to stick to a diet.
Glucagon-like peptide-1 (GLP-1)
A second hormone released by intestinal L cells is GLP-1, a peptide with a short plasma halflife of 2 minutes due to rapid cleavage by protease DPP4 (Dipeptidyl peptidase-4). GLP-1 increases insulin secretion from pancreatic β-cells in a glucose-dependent manner and inhibits release of glucagon. It also enhances satiety centrally via neurons in the area postrema expressing GLP 1 receptors.
Pharmacology cross reference:
Two classes of diabetes drugs are used to increase GLP-1like activity:
• GLP-1 agonists like exenatide, liraglutide • DPP4 inhibitors like sitagliptin Because they target the same pathway, it does not make sense to combine them. In addition, liraglutide is approved in a higher dose (3 mg daily) to support weight loss in obesity, but is not reimbursed by health insurance for this indication. It is injected with a pen.
Ghrelin
Ghrelin is considered the main counter player of leptin. It is produced during fasting by distinct cells within the mucosal layer of the stomach, especially in the fundus, and in the pancreas. Sleeve gastrectomy, a bariatric surgery procedure, removes a large part of the gastric fundus, thereby strongly reducing ghrelin production.
Ghrelin (acronym for growth hormone release inducing) is a 28 amino acid peptide with a linked octanol group. Ghrelin activates its receptor, GHSR (GH secretagogue receptor), which is expressed in the hypothalamic Nucleus arcuatus as well by afferent neurons of the vagus nerve. Ghrelin stimulates the sensation of hunger and appetite as well as the release of growth hormone. It is suppressed by physical exercise. In summary, ghrelin contributes to increasing body weight and growth.
DIGESTION AND ABSORPTION OF CARBOHYDRATES
The better part of nutritional carbohydrates is taken up in the form of starch. Starch digestion starts with the enzyme α-amylase, which is present in saliva and pancreatic juice. In between, in the stomach, carbohydrate digestion is paused, as α-amylase is inactivated by gastric acid. α-Amylase is an endoenzyme able to break internal α-1,4-glycosidic linkages between glucose units, but not terminal ones or linkages adjacent to α-1,6-linkages. Therefore, α-amylase digestion does not result in monosaccharides, but rather in packs of two (maltose) or three glucose units (maltotriose) and α-limit dextrins, containing α-1,6-branch points and adjacent linkages.
Carbohydrate digestion is completed by three brush border enzymes: maltase (glucoamylase), lactase and sucrase-isomaltase. Maltase cleaves maltose, maltotriose and longer 1,4-linked glucose polymers. Lactase breaks the lactose disaccharide into its galactose and glucose monosaccharide units. Sucrase-isomaltase in fact consists of two enzymes directly attached to each other. The sucrase moiety splits the sucrose disaccharide (the sugar from the sugar bowl) into its glucose and fructose units. Only the isomaltase moiety is able to break the α-1,6glycosidic bonds of limit dextrins; it is also able to cleave α-1,4-linkages.
Finally, the resulting monosaccharides are absorbed into enterocytes with the help of transporters. Glucose import is driven by a Na + electrochemical gradient. One glucose unit and two sodium ions are cotransported by the Na + -coupled glucose transporter (SGLT1). Thus, moderate dehydration should be treated with a combination of electrolytes and glucose or carbohydrates, as the added glucose increases the rate of Na + absorption. SGLT1 is able to ferry glucose as well as galactose into the enterocyte, but not fructose, which forms a fivemembered ring. Fructose is absorbed via GLUT5. At the basolateral side, all three monosaccharides exit the cell via GLUT2.
Glycemic index
Eventually, the majority of all food carbohydrates appear in the blood in the form of glucose. Depending on food composition, the rise in plasma glucose concentration may be fast, producing a spike, or more protracted. To express this property in the form of a simple number, the glycemic index was created. The glycemic index (GI) of a food is defined as the area under the curve of plasma glucose concentration over two hours in response to an amount of the food containing 50g carbohydrates, in relation to that of a pure 50g glucose meal, times 100. Thus, glucose has a glycemic index of 100; "high glycemic index foods" like white bread, potatoes, most white rice varieties, most processed breakfast cereals are around 70 or higher; "low glycemic index foods" like whole grains, pure dairy products or most fruits or vegetables are around 55 or less. (Caution: in some, mostly US, tables, a standard of white bread instead of glucose is used, resulting in different values). GI is attributed great importance in many popular diet systems, including the Glyx diet, South Beach Diet, etc. Is that warranted?
Intake of high glycemic index foods causes a postprandial spike in glucose concentration, followed by a commensurate spike in insulin secretion. During the following hours, this promotes carbohydrate oxidation at the expense of fat oxidation, while surplus glucose is converted to fat. In controlled experiments in animals, e. g. in rats, high-GI-fed animals developed more body fat and insulin resistance compared with control animals fed a low-GI diet of otherwise identical composition, including identical total carbohydrate content.
There is considerable disagreement in the literature as to what extent this concept is valid in humans. Experiments in humans cannot be done with the same rigor. Necessarily, changes in GI influence fiber content, texture, sugar content and therefore palatability of foods. We all tend to eat more of a food if it tastes good. At its core, obesity is foremost the result of a positive caloric balance; if at all, the glycemic index plays a role secondary to that. Still, in the absence of definitive evidence, to be on the safe side, it seems like a good idea to emphasize low-GI foods in nutrition.
Practical implications: For breakfast, consider replacing processed cereals or white bread with whole-grain muesli containing yoghurt and fresh fruits.
Lactose intolerance
Lactase is one of the disaccharidases located in the brush border of the enterocyte. It breaks the lactose disaccharide into glucose and galactose. While the enzyme is expressed at high levels in babies, expression levels decline with age. Therefore, adults worldwide tend to suffer from lactose intolerance. Exceptions are descendants of populations who traditionally relied on dairy farming, like in northern Europe. Here, nutrition exerted a selective force over thousands of years, favoring those individuals who were able to maintain lactase expression longer than others. This ability is based on a single SNP 14,000 bases upstream of the lactase gene: the position is normally occupied by a C, while in descendants of northern European dairy farmers a T creates a binding site for the transcription factor Oct1. This addition of an upstream transcription factor sustains persistent expression of the lactase gene. In other words, lactose "intolerance" is the norm, lactase persistence the exception. This explains why lactose "intolerance" is the norm in people of African or Asian descent, but rarely occurs in Scandinavia. Within Europe, lactose intolerance increases from north to south; In the German-speaking countries about 15% are affected, in the Mediterranean countries, percentages are much higher.
Disaccharides cannot be taken up by enterocytes. Due to the osmotic effect of uncleaved lactose, as well as by secondary changes in bacterial colonization, affected individuals suffer from flatulence and diarrhea in response to intake of lactose-containing food (milk, ice cream, cheese, chocolate,...). As colonic bacteria produce H 2 when metabolizing lactose, breath H 2 in response to an oral dose of lactose may be measured to test for lactase deficiency.
Fructose-malabsorption
The capacity of fructose transporter GLUT5 is limited and varies between individuals. If fructose intake exceeds absorptive capacity, remaining intestinal fructose causes diarrhea and flatulence by osmotic effects and bacterial metabolization. Foods rich in fructose include the sugar in our sugar bowl, fruit, honey and corn syrup-containing industrial foods. A high percentage of people with European roots suffer from fructose malabsorption. Fructose malabsorption is not to be confused with the rare hereditary fructose intolerance (HFI). The enzyme missing in HFI, aldolase B, is required to break fructose into two three-carbonmolecules in the liver.
Fructose controversy
The fructose content of the Western diet is high, due to high uptake of sucrose, the use of high fructose corn syrup in industrial-manufactured food and the use of fructose in soft drinks. Following absorption, fructose is quantitatively extracted and metabolized by the liver. This requires a lot of ATP, which is hydrolyzed to AMP, part of which is degraded to uric acid. High fructose consumption seems to moderately increase the risk of gout. Following metabolization in the liver, part of the fructose load is released as glucose and lactate, part used for lipogenesis, increasing the risk of non-alcoholic fatty liver disease. In rodents, high fructose feeding causes insulin resistance and there is a long controversy to what extent that may also be true for the actual levels of fructose consumption in humans.
A meal leading to an increase in blood glucose causes pancreatic beta cells to secrete insulin. A comparable load of fructose releases far less insulin: due to "fructose-vacuuming" by the liver, the low plasma levels of fructose (<0.5 mM, compared to 5.5 mM = 100 mg/dl for glucose) allow only small amounts to enter beta cells via GLUT2. Recall that insulin, together with leptin, acts as a satiating signal in the hypothalamus. A person consuming fructose is therefore likely to feel less satiated than a person consuming an isocaloric amount of glucose. Indeed, food craving was shown to be stronger in the same individuals after ingestion of a fructose-containing than after a glucose-containing soft drink. Fructose may therefore accentuate our more general problem of overfeeding with simple sugars resulting in weight gain, lipotoxicity and insulin resistance.
IRON
Iron is a limiting resource for many biological systems. Humans and animals need iron to handle oxygen, in hemoglobin and myoglobin as well as in cytochrome enzymes. About 2 billion people, more than a quarter of the world population, are iron deficient; about 500 million suffer from manifest iron deficiency anemia. Fungi and bacteria need iron as well, and go to great lengths to obtain it. One way our body limits infections is by depriving these microorganisms of iron.
Dietary iron is primarily absorbed in the duodenum. It comes in two forms: still integrated in heme or free. The majority of heme iron stems from myoglobin in red meat. It is absorbed en bloc with the heme group by a special transport mechanism, a process which is more efficient than absorption of free iron. Heme iron is only released within the cell. Intestinal nonheme iron may be ferric (Fe 3+ ) or ferrous (Fe 2+ ). Fe 3+ is not soluble at pH values above 3; it forms stable complexes with many anions and is not readily absorbed. Fe 2+ is soluble up to pH 8; it is cotransported with protons by the divalent metal transporter (DMT1). In all, only 10%-15% of dietary iron is absorbed. Iron-binding tannins from tea or the alkaline pH of dairy products further reduce this percentage.
Iron is exported from the duodenal enterocyte by the solute carrier ferroportin, an iron exporter expressed by all cells. Fe 2+ is dangerous due to its ability to generate hydroxyl radicals. On export, it is therefore oxidized to Fe 3+ with the help of copper-containing hephaistin.
In the circulation, Fe 3+ is then ferried around by transferrin. Blood plasma, too, contains a copper-containing enzyme able to convert Fe 2+ to Fe 3+ , ceruloplasmin.
If cellular iron levels are low, uptake from blood is increased via an elegant mechanism. The mRNA for the transferrin receptor contains several iron response elements (IRE) in its 3' untranslated region. IREs form characteristic stem-loop structures. At low cellular iron levels, these structures are bound by specialized proteins termed IRE binding proteins (IRE-BPs) or iron regulatory proteins (IRPs). By binding the stem-loop structures, the proteins protect the mRNA from being degraded by RNases, resulting in high expression levels of the transferrin receptor and high iron uptake. Once iron levels have been restored, Fe 2+ binds to iron regulatory proteins, thereby modifying their structure in a way that they cannot bind to IREs anymore. This destabilizes the transferrin receptor mRNA, leading to lower expression and lower Fe 2+ uptake from the circulation.
Iron response elements are also used the other way round: in the ferritin mRNA, a single element is present in the 5' untranslated region, in front of the translation initiation codon. At low intracellular Fe 2+ levels, the IRE is bound by IRE-BP and translation is blocked; high Fe 2+ levels remove the IRE-BP, allowing vigorous translation of the mRNA and high-level expression of this Fe 2+ storage protein. Ferritin storage of excess iron occurs mainly in the liver. Although most of the ferritin is within cells, plasma levels, which are in equilibrium with intracellular stores, may be used to monitor iron reserves.
Combined, the mechanisms described up to this point would regulate intracellular iron levels, but would over time still result in iron overload by continuous enteric uptake. To prevent that, the liver is the starting point of an additional negative feedback loop. Extracellular iron levels are sensed by hepatocytes by a protein complex including the transferrin receptor and transmembrane protein HFE ("high Fe"). Adequate iron levels lead to induction and secretion of hepcidin, a 25 amino acid-peptide. Hepcidin causes ferroportin internalization and degradation, blocking iron export from all cells. So, if serum iron is adequate, ferroportin is blocked in all cells, including duodenal enterocytes. As intracellular iron in duodenal cells accumulates, uptake from the intestinal lumen decreases.
As we have already seen in our occupation with the immune system, hepcidin is also induced by inflammation via a second regulatory mechanism. IL-6 and other inflammatory cytokines induce an acute phase response in the liver, which includes secretion of hepcidin. As we saw before, hepcidin blocks the export of iron from cells. In this case, the cells most affected are macrophages, which contain high levels of iron from erythrophagocytosis, the constant breakdown of aging erythrocytes. In addition, ferroportin expression in macrophages is downregulated by inflammatory cytokines and directly by TLR4-activation. Together, these mechanisms sequester the iron in the reticuloendothelial system and deprive the infecting microorganisms from required iron. During an acute infection, this artificial "internal iron deficiency" does not result in negative consequences. However, in chronic infection, it may cause anemia in the face of abundant reserves of iron in the reticuloendothelial system. The iron, although present in macrophages, is not available to erythroid progenitors.
Therefore, the serum concentrations of iron and transferrin saturation are reduced in both iron deficiency anemia and in anemia of chronic inflammation. Ferritin is low in iron deficiency anemia but normal or increased in anemia of chronic disease; but keep in mind that the two forms of anemia may coincide.
Hemochromatosis
Iron overload has toxic effects. Overload may be the result of frequent transfusions or of certain forms of hemolytic anemia; alternatively, it may the manifestation of a common inherited disorder, hemochromatosis. The majority of hemochromatosis patients carry mutations in their HFE ("high Fe") genes, typically Cys282Tyr. In the absence of normal HFE, hepcidin expression by hepatocytes is inadequate, resulting in unchecked iron uptake from the intestine. For many years, iron accumulates without causing symptoms. Once buffering mechanisms are overwhelmed, iron overload leads to cirrhosis of the liver, diabetes mellitus, arthritis and a bronze pigmentation of the skin. Via hepcidin, total body iron is normally regulated between 2 and 6 g. In hemochromatosis, this amount grows by 0.5-1 g per year, sometimes reaching a total of 50 g or more. In males, symptoms usually don't start until they reach their forties; females are not affected due to their monthly period. Therapy is medievally simple, but effective: phlebotomy until the iron overload is corrected. Originating in Northern Europe only 1200-1400 years ago, the C282Y mutation is surprisingly common in people with European roots: about 10% are heterozygous, 1 person in 200-400 homozygous. Even among male homozygotes, only a part develops clinical symptoms. The frequency of this recent mutation suggests some selective advantage. Affected women may have an easier time compensating their monthly losses of iron. Macrophages, which are irondepleted in hemochromatosis, in this state may be better able to kill off infecting intracellular bacteria such as Mycobacterium tuberculosis or Salmonella typhimurium.
FOLATE
Folate is present in many vegetables, e. g., in spinach, lettuce, broccoli and beans, in liver and liver products and, as aficionados never fail to emphasize, in beer. In its tetrahydrofolate (THF) form, it is essential for nucleotide biosynthesis (purines and thymidine) and with that, for all rapidly proliferating cells. Furthermore, it is required for additional 1-carbon transfers in many biosynthetic pathways, like that of methionine. Depending on the specific reaction, the coenzyme is active in one of several forms: for example, synthesis of dTMP from dUMP requires 5,10-methylene-THF, while methionine synthesis is dependent on N 5 -methyl-THF.
From natural sources, folate is taken up mainly in polyglutamate form. In the duodenum, the conjugated glutamates are taken off one by one by a brush border peptidase, except for the last one. Folate is then absorbed by exchange against a hydroxyl ion (OH -). It is then transported to the liver, where it is reduced first to dihydrofolate (DHF) and then to its active form THF by the enzyme dihydrofolate reductase (DHFR). From there, it is "loaded" with a 1-carbon group from the side chain of serine.
Folate deficiency results in problems in all rapidly proliferating tissues. Clinical symptoms usually develop in the form of anemia. As the number of erythrocytes produced is too low, in a compensatory mechanism they are at least stuffed with as much hemoglobin as possible, resulting in megaloblastic anemia. However, their increased size makes it harder for them to squeeze through the meshwork of the reticuloendothelial system, expediting their break down in the spleen.
Cell proliferation is especially high during the embryonic and fetal periods, and folate deficiency may lead to neural tube defects like spina bifida. Therefore, pregnant women are routinely substituted with folate. As neural tube defects originate very early in pregnancy, it would be advisable for women to take folate even before conception.
VITAMIN B12
One of the most complex "small" molecules of our body is vitamin B12, or cobalamin. So far, we know of only two reactions for which B12 is required: the synthesis of methionine and the "debranching" of methylmalonate, an intermediate product in the breakdown of oddnumbered fatty acids and amino acids. In the synthesis of methionine, B12 cooperates with N 5 -methyl-THF, from which it accepts the methyl group that is then transferred to the sulfur atom of homocystein. Vitamin B12 is synthesized only by certain bacteria, yet required by an enormous food chain, ranging from many other bacteria to all animals. As it is not present in vegetables of fruit, we take it up in the form of animal products: meat, fish, eggs and, to a limited extent, dairy products.
Vitamin B12 is absorbed in the ileum only and has to be protected from digestion until it arrives there. In the acidic environment of the stomach, it is bound by haptocorrin (or "Rprotein"), produced by salivary and gastric glands. In addition to acid, parietal cells produce intrinsic factor (IF), a glycoprotein which initially cannot bind B12 at the acidic pH in the stomach. In the duodenum, haptocorrin is digested by pancreatic proteases, and IF takes over. The B12:IF complex is highly resistant to the digestive onslaught in duodenum and jejunum. On arrival in the ileum, the complex is specifically bound and taken up into the enterocyte by receptor-dependent endocytosis. The process absolutely requires IF; free cobalamin is neither bound nor absorbed. In the enterocyte, the complex dissociates, and B12 is taken over by the protein transcobalamin, which is also instrumental in exocytosis and transport to the periphery and to the liver. A large pool of B12 is constantly subjected to enterohepatic circulation: excreted with bile und reabsorbed in the ileum.
Pernicious anemia
A problem in any one of the many systems required for its absorption leads to vitamin B12 deficiency. A strictly vegetarian or vegan diet contains inadequate amounts of vitamin B12. Another frequent cause of deficiency is an autoimmune reaction against parietal cells, which produce acid and intrinsic factor. The liver stores one or two years' worth of vitamin B12, meaning symptoms of deficiency develop very gradually. The symptoms are those of folate deficiency. Lack of vitamin B12 blocks all of the body's folate reserves in the N 5 -methyl-THF form, leading to a secondary shortage of 5,10-methylene-THF (the reaction from 5,10methylene-THF to N 5 -methyl-THF is irreversible; THF can only be regenerated if the methyl group is taken over by B12 to synthesize methionine). Yet, 5,10-methylene-THF is absolutely required to produce dTMP. Another deficient derivative, N 10 -formyl-THF, is required for de novo synthesis of purines. Hence, B12 deficiency results in the same megaloblastic anemia as folate deficiency. Additional symptoms are a distinctive glossitis and neurological problems, starting with peripheral polyneuropathy. Still later, the CNS is affected with weakness, ataxia, memory impairment and depression. Weakness and ataxia are the result of demyelinization of the dorsal columns of the spinal cord, a syndrome termed funicular myelosis. The details of its pathophysiological mechanism have not been resolved.
SELENIUM
Let us take a look at Selenium as just one example of important micronutrients. Selenium is in the same group of the periodic table as oxygen und sulfur, meaning it is quite reactive and eager to take over electrons. At the same time, its readiness to give electrons back is higher than that of halogens. Selenium is essential for vital redox reactions, like the detoxification of H 2 O 2 by glutathione peroxidase, and for the activation and inactivation of thyroid hormone by deiodination. It is inserted into proteins in the form of a special rare amino acid, selenocystein, which carries a selenium atom at the position of the usual sulfur (or oxygen in the parallel structure of serine). In the genetic code, there is no dedicated codon for selenocystein. Instead, one of the three stop codons, UGA, can be interpreted as a selenocystein codon with the help of a specific translation factor. This factor binds to a signal loop structure in the 3'-UTR of the mRNA encoding the enzyme in question.
In most places, there is no need to worry about selenium. However, low levels of natural selenium in the ground and thus in food are found in certain defined regions, notably in China. There, selenium deficiency may lead to Keshan disease, which is characterized by congestive cardiomyopathy that may be fatal.
FATTY ACIDS
Digestion and absorption of fats is covered in the lecture notes on liver function. Here, we will only consider the nutritional debate on fatty acids.
Depending on their source, fats contain a range of different fatty acids. Saturated fatty acids, incorporated in triglycerides, form the majority of our own body fat, and the same is true for pigs, cattle and sheep. Thus, meat and dairy products from these animals contain mainly saturated fats. Examples are palmitic acid (16:0) and stearic acid (18:0; the first number indicates the number of C atoms, the second number those of the double bonds). Palm oil, the least expensive dietary fat, contains about 40% palmitic acid and 40% monounsaturated oleic acid. Unsaturated fatty acids contain at least one double bond. Our body is able to synthesize monounsaturated fatty acids, like oleic acid (18:1), but not polyunsaturated fatty acids (PUFA). PUFA are synthesized by plants, and we have to take up at least two of them to survive, linoleic acid (18:2) and α-linolenic acid (18:3), from which we can synthesize the others. These two are therefore called essential fatty acids. Certain plant oils are therefore rich in PUFA. Fatty fish, too, contain ample PUFA which are originally synthesized by algae and taken up via the food chain.
There is no doubt that the mixture of fatty acids we consume with our diet affects our health. Most of what we know comes from nutritional studies, where the human body is treated as a black box: nutritional input is correlated with output in the form of health parameters of cohorts or large populations. The molecular mechanisms behind these correlations remain largely in the dark. Numerous hypotheses have been put forward but remain insufficiently tested.
Discussions on fatty acids have centered on two topics: n-3/n-6 and trans fatty acids.
n-3/n-6 polyunsaturated fatty acids
Depending on the position of the double bond nearest to the methyl end of the carbon chain, the majority of polyunsaturated fatty acids fall into one of two main groups:
• n-3 (sometimes referred to as omega-3) PUFA, like α-linolenic acid (18:3), eicosapentaenoic acid (EPA; 20:5) and docosahexaenoic acid (DHA; 22:6). Fatty fish is rich in n-3 fatty acids. The only oilseed that contains predominantly α-linolenic acid is linseed or common flax, which has been cultivated in Europe since the Neolithic period. Linseed oil has a marked propensity to oxidize, becoming bitter, then hardening and is therefore rarely used as food oil.
• n-6 PUFA, like linoleic acid (18:2) and arachidonic acid (20:4). A number of vegetable oils contain predominantly linoleic acid: sunflower oil, corn oil, soybean oil, safflower oil and walnut oil.
Greenland Inuit were found to have very low levels of coronary heart disease despite a fatrich diet derived almost exclusively from animal sources. As their intake of long-chain n-3 PUFA from fish was very high, a causal link was proposed. Cohort studies and randomized clinical intervention studies using fish oil supplementation have led to contradictory results, but the weight of the data seem to support a decrease in coronary heart disease with higher intake of n-3 PUFA. The mechanism remains unclear. On the other hand, positive effects on arteriosclerosis were also described for n-6 PUFA. Two aspects are probably important: 1. that we absorb sufficient PUFA in relation to saturated fatty acids 2. that the PUFA are in a favorable ratio n 3: n 6. A ratio of at least 1: 5 is recommended; in our western diet, however, the actual ratio is around 1:15.
Trans fatty acids
Unsaturated fatty acids exist in either of two configurations: cis or trans. Cis means, the carbon chains sit at the same side of the bond axis, producing a kink in the fatty acid. This kink makes a bunch of cis-acids awkward to stack (they literally "don't stack up"), while rodstraight saturated acids and nearly-straight trans-unsaturated acids are stacked easily. In other words: saturated and trans-unsaturated fatty acids, and the lipids containing them, stick together and have relatively high melting points, whereas cis-acids have a low melting point.
For example, C-18 saturated stearic acid has a melting point of 69°C, mono-unsaturated trans acid elaidic acid one of 45°C, while the respective cis-acid, oleic acid, has a melting point of just 17°C. Thus, at body temperature of 37°C, complex lipids containing cis-unsaturated fatty acids tend to be more fluid than their saturated or trans-unsaturated counterparts, which tend to stick together. Lower fluidity, however, can not explain the observed negative effects of trans fatty acids, since our organism contains plenty of saturated fatty acids which are even less fluid. By their kink, trans fatty acids have been proposed to block enzymes, interfering with metabolization of other fatty acids. While there is yet no agreement on exact mechanisms, trans fats are associated with increased risk for arteriosclerosis, coronary heart disease and stroke. In addition, trans-fats have been reported to raise "bad" LDL cholesterol and to lower "good" HDL cholesterol.
So, we'd like more cis-fats and less trans-fats. Where do they come from, anyway?
Cis fats represent the bulk of vegetable fats, which, due to their low melting point, form liquid oils after extraction. Examples are olive oil (75% oleic acid, 10% linoleic acid, 15% saturated), canola oil (60% oleic acid, 20% linoleic acid, 10% α-linolenic acid, 7% saturated, up to 4% trans fats through the refining process), corn oil (50% linoleic acid, 30% oleic acid, 15% saturated), soybean oil (55% linoleic acid, 25 oleic acid, 10% saturated) and sunflower oil (65% linoleic acid, 20% oleic acid, 10% saturated). A cultivar to reduce linoleic acid, high oleic acid sunflower oil (80% oleic acid, 10% linoleic acid, 10% saturated) approaches the composition of olive oil. Percentages given are only rough indications, as there is considerable batch-to-batch variability.
Trans fats occur naturally in ruminants such as cattle and sheep as a small percentage of their total fat. For example, butter (70% saturated, 20-25% oleic acid) may contain up to 4% of trans-fats. Therefore, pre-industrial humans consumed low amounts of trans-fats. This changed with industrial food production. While plant oil is cheap to produce, it oxidizes (turns rancid) more quickly, it is difficult to transport and you cannot spread it on your bread. So, ways to harden plant oil (i.e., increase its melting point) were developed, which relied on partial hydrogenation. The idea is to add hydrogen back to unsaturated fatty acids, converting part of them to saturated acids and reducing the number of double bonds in the rest. However, this process has the setback of switching a considerable percentage of fatty acids into the trans configuration. The process results in much larger amounts of trans fatty acids than occur naturally. In essence, we convert good nutritional fats to bad fats. These partially hydrogenated fats rich in trans-fats displaced natural solid fats in many areas, especially in industrially produced baked goods, snacks, fast foods and restaurant staples.
For a long time, the adverse medical effects of trans fats remained underappreciated. During the last few years, growing awareness has led to widespread legislative efforts to strongly reduce trans fats in industrially produced food components.
To reduce cardiovascular disease, the WHO recommends since 2018 to limit saturated fats to 10% of daily caloric intake and trans fats to a maximum of 1%.
PROTEIN DIGESTION STARTS IN THE STOMACH
Digestion of food proteins is initiated by the joint action of acid and pepsinogen in the gastric "food mixer". In the stomach, little happens in the way of carbohydrate or fat digestion.
Proteins are pretty hard to "crack", as their folding protects them from protease attack. The first cut inside the chain of amino acids is the most difficult one. Once that has been made, the fragments tend to lose part of their protective folding structure and may be broken down more easily. Very high proton concentrations (stomach pH can fall to about 1) denature (unfold) parts of proteins, thereby enabling these critical first cuts. Proteases are categorized by the chemical group used to break a peptide bond: the main families are serine, cysteine, aspartic and metalloproteases. The ability of an endopeptidase to cleave a peptide bond depends on the amino acid sequence of the substrate protein. The stomach's main protease, pepsin, is an aspartate protease cutting next to nonpolar amino acids, especially bonds following phenylalanine. Due to these sequence limitations, a set of different proteases is required to degrade proteins efficiently.
The components of gastric juice are secreted by numerous mucosal glands, which contain different types of cells. Mucous neck cells produce protective mucus, chief cells secrete pepsinogen, (neuro)endocrine cells release signaling molecules. Antral G cells, e. g., produce gastrin, while D cell-produced somatostatin inhibits gastrin release. Stem cells and their early progeny, transit amplifying cells, maintain a cell population subject to rapid turnover. Acid is produced by parietal cells.
Upon stimulation, parietal cells are able to increase their secretory surface by a factor of 50-100 by fusing tubulovesicular membranes into their "canalicular" apical membrane. Acid is secreted by an H + /K + -ATPase pumping protons into the lumen in exchange for K + . The K + recycles back into the lumen via K + channels, followed by Cl -. To generate protons, the parietal cell takes up CO 2 and H 2 O, converting them to H + and HCO 3 with the help of carbonic anhydrase. HCO 3 exits the cell across the basolateral membrane in exchange for Cl -. The net result is secretion of HCl into the gastric lumen, a process that is activated by two types of stimuli: acetylcholine from vagal neurons and gastrin from antral G cells. These stimuli activate parietal cells both directly and indirectly, via activation of histamine-secreting neuroendocrine cells below the epithelium, so-called ECL (enterochromaffine-like) cells. Parietal cells receive the indirect signal via H2 histamine receptors.
Pharmacology cross reference:
Proton pump inhibitors like omeprazole bind covalently to cysteine at the cytosolic part of the H + /K + -ATPase, inactivating it irreversibly. The effect is sustained until pumps have been replaced by resynthesis, which takes more than a day. Histamine H2-receptor antagonists like ranitidine, which inhibit acid production to a lower extent, have been largely replaced by proton pump inhibitors.
Pepsinogen is the product of chief cells. It is secreted in response to a range of neuronal and hormonal stimuli, most importantly acetylcholine from vagal neurons. Pepsinogen is activated by acid. At low pH, it spontaneously splits into an N-terminal peptide and active pepsin. Efficient spontaneous cleavage occurs only below pH3, followed by a positive feedback mechanism in which activated pepsin cleaves more pepsinogen. Pepsin is an endopeptidase with a pH optimum between 1.8 and 3.5; above that range, pepsin is inactive. Pepsin digestion results in large peptide fragments, called peptones. Peptones in turn activate G cells in the stomach's antrum to secrete gastrin, as well as I cells in the duodenal and jejunal epithelium to secrete cholecystokinin.
To summarize the role of stomach acid: acid helps breaking peptide bonds; at very low pH, there is a steep increase in spontaneous hydrolysis. In addition, acid causes proteins to denature, making them accessible to proteases. Finally, stomach acid kills the majority of all bacteria, protecting us from infections. All these benefits stand in marked contrast to one major disadvantage: of course, hydrochloric acid would have the same aggressive effects on the epithelial lining of the stomach. Thus, to protect epithelial cells, a constantly renewed mucus gel layer of neutral pH is absolutely required.
Mucus-producing cells sit at the surface of the mucosa, as well as in the pit and at the neck of gastric glands. Mucus consists of long sulfated carbohydrate chains bound to tetramers of the glycoprotein mucin. Due to their strongly polar nature, these proteoglycans are always wrapped in a cloud of hydration. This semi-solid mucus gel layer is alkalized by HCO 3 -, thus forming a neutralizing barrier which protects gastric epithelial cells. Rising like a moving stairway, the mucus gel layer is constantly renewed from below and digested from above. HCO 3 produced by mucous cells remains captured in the gel layer meshwork.; active pepsin is excluded. The few pepsin molecules that make it into the meshwork are rapidly inactivated by the rising pH gradient. Production of HCO 3 and mucus depend on locally produced prostaglandin E (PGE), which is synthesized via cyclooxygenase-1 (COX-1).
In case we intend to administer drugs via the oral route, gastric acid is frequently a challenge regarding galenic formulation. Some pharmaceuticals would be inactivated by gastric acid; others might damage the gastric mucosa. One example is proton drug inhibitor omeprazole proper, which in the stomach needs to be protected from acid. One option is to coat tablets with an acid-resistant layer. However, that may cause the pills to remain in the stomach much longer than intended. After all, the stomach is a mixing machine with the task of keeping protein-rich food in an acidic environment for a long time. To prevent peristalsis from pressing out too much chymus prematurely, the pylorus contracts in a way that only particles of less than 2 mm diameter may pass. Paradoxically, larger particles are retained in the stomach until it is nearly empty. Only then, the pylorus slackens, allowing the last larger particles to pass into the duodenum. If the patient eats several times a day, that may cause a so-called monolithic gastro-resistant tablet to remain in the stomach for multiple hours, being released and starting its (or their, with a 3x1 drug regimen) intended pharmaceutical action only late during the night. The problem may be solved by MUPS (multi-unit pellet system), where gastro-resistant pellets with diameters below the critical 2 mm are consolidated into a larger tablet. In the stomach, the pill disintegrates into pellets which are able to pass the pylorus individually. Expensive! 13. GASTRITIS AND GASTRIC/DUODENAL ULCER The hallmark of gastritis is superficial epithelial erosions due to a reduction of the protective barrier. A peptic ulcer, a deeper, localized lesion in the gastric or duodenal mucosa, has an extremely hard time to heal under the constant barrage of acid and pepsin. Until proton pump inhibitors became available and before Helicobacter-infection was recognized as a curable cause of ulcers, frequently the only way out was to surgically resect the larger part of the stomach.
Helicobacter pylori is unusually resistant to acid. It preferentially colonizes the mucosa of the antrum, away from the fundus region where acidity is highest because parietal cells are most prominent. It moves towards the more neutral end of an acid gradient, uses proteases to digest its way into the mucus and attaches to gastric epithelial cells. By cleaving urea, it produces its own private HCO 3 − -buffer plus NH 4 + . Proteases as well as NH 4 + have toxic effects on adjacent epithelial cells. Only some strains of H. pylori are pathogenic: they contain a genome section termed cag-pathogenicity island (cag stands for cytotoxin-associated gene). Encoded genes enable the bacterium to inject peptidoglycan components into mucosa cells, where these are recognized by NOD-like receptors. The resultant inflammatory reaction breaks up the epithelial barrier, further increasing the bacterium's chances of survival. The changes lead to an increase in production of gastrin, boosting acid production overall. While only some of those infected develop symptoms, H. pylori causes the majority of gastric und duodenal ulcers, with NSAIDs a distant second at less than 20%. Ten to twenty percent of those infected develop an ulcer over their lifetime. Infection may be assessed via the carbon urea breath test, in which 13 C-oder 14 C-labeled urea is broken down to radioactive CO 2 . A drink containing urea is consumed, exhaled 13 C-CO 2 is measured.
Non-steroidal anti-inflammatory drugs (NSAIDs, like aspirin and ibuprofen) and glucocorticoids, the two drug families prescribed most frequently to combat inflammation, inhibit synthesis of prostaglandin E via different mechanisms. As an unwanted side effect, this also happens in gastrointestinal mucosa, reducing secretion of HCO 3 − and diminishing production of the mucus gel layer. As a result, formation of ulcers and gastrointestinal bleeding are among the dreaded complications of long term antiinflammatory therapy. Proton pump inhibitors are used routinely to counter this effect. Unfortunately, as its name implies, gastric protection protects only the stomach, but not the intestines, while negative effects of NSAIDs affect the mucosa of the entire gastrointestinal tract. While COX-1 is constitutively expressed in all cell types, COX-2, which is induced in macrophages and other inflammatory cells, produces the majority of prostaglandins in inflammation. To reduce unwanted effects, COX-2 inhibitors were developed, which turned out to be only a partial success: COX-2 inhibitors don't upset the gastrointestinal tract as much yet were found to cause a higher rate of atherothrombotic complications.
PROTEIN DIGESTION AND ABSORPTION
From the stomach, small batches of chyme (semiliquid food mass) are released into the duodenum by the pylorus (gatekeeper). The mixture is acidic and contains the products of pepsin digestion, peptones. Acidic pH stimulates S cells in the duodenal epithelium to produce secretin, which stimulates pancreatic duct cells to produce HCO 3 − . Peptones stimulate I-cells in the duodenal and jejunal epithelium to secrete cholecystokinin (CCK). CCK mediates satiety and induces the release of bile from the gallbladder and stimulates the exocrine pancreas. Together, secretin and CKK cause the release of the pancreatic cocktail of digestive enzymes in a considerable volume of alkaline secretion, neutralizing the chyme.
In the duodenum, protein digestion is continued by a series of pancreatic enzymes with optimal operating pH in the slightly alkaline range. Once more, these are secreted as inactive proenzymes: trypsinogen, chymotrypsinogen, proelastase, proprotease E and carboxypeptidases A and B. A brush border enzyme, enteropeptidase (enterokinase), cleaves trypsinogen into active trypsin and a terminal peptide. Trypsin proceeds to activate additional trypsinogen molecules as well as the other proteases and peptidases. Trypsin, a serine protease, breaks peptide bonds following positively charged amino acids lysine and arginine. Closely related chymotrypsin prefers bonds following phenylalanine, tyrosine, tryptophane and methionine. The two carboxypeptidases are exopeptidases, nibbling amino acids one by one from the C-terminus. Altogether, protein digestion results in single amino acids (30%) and small peptides of a few amino acids (70%).
The following two steps in protein digestion are accomplished by enterocytes via a number of brush border peptidases and cytosolic peptidases. Brush border exopeptidases further break down peptides, and carriers for tetra-, tri-and dipeptides (PepT1) as well as for single amino acids cotransport the material into the cell together with either protons or sodium. In the cytosol of the enterocyte, tetra-, tri-and dipeptides are broken down into single amino acids, which are then released into the portal blood at the basolateral side.
The mechanisms described above serve solely to take up amino acids. In addition , but only to a small extent, larger peptides and complex proteins are ferried across the epithelial barrier. This is the main responsibility of M cells, specialized cells in the intestinal epithelium covering Peyer's patches (please see lecture notes on immunology). This enables the immune system to survey the contents of the intestine.
PANCREATITIS
Pancreatic juice is, even more than gastric juice, a biochemical bomb. Normally, this bomb is secured by multiple safety mechanisms. Proteases are being produced as inactive precursors. Packaged in secretory granules, these are kept away from critical cell components. As an additional precaution, pancreatic trypsin inhibitor is co-packaged into the granules, buffering up to 10% of accidentally activated trypsin. The granule contents are kept at a low pH, at which pancreatic enzymes remain inactive.
In spite of all these precautions, occasionally, the enzymatic cascade is triggered inside the pancreas, promptly resulting in its self-digestion. The most frequent triggers are gallstones blocking the papilla of Vater and liberal consumption of alcohol. The chain of causation between these triggers and acute pancreatitis is incompletely understood. If gall backs up due to concrements, its components damage pancreatic cell membranes, increasing their permeability. Sometimes, a stone may form sort of a valve, letting in activated enzymes from the duodenal lumen. Intake of alcohol may stimulate secretion to such an extent that lipase from backed-up pancreatic juice starts to damage cell membranes. In contrast to proteases, lipase is already secreted in an active form.
Some genetic polymorphisms may predispose for pancreatitis, which thus may run in families. Pancreatic trypsinogen is the product of several distinct genes. By their charge, trypsinogen variants may be separated by electrophoresis. A specific mutation, Arg122His, of the main variant, cationic trypsinogen (Gene: PRSS1 for protease, serine, 1), makes activated trypsin resistant to breakdown by other trypsin molecules. As a result, this form of trypsin stays active much longer, predisposing the individual for pancreatitis. As one mutated allele is sufficient, the predisposition is inherited as a dominant trait. Mutations in trypsin inhibitor (Gene: SPINK1 for Serine Protease INhibitor, Kazal-type 1) interfere with its ability to buffer autocatalytically activated trypsin. SPINK1 mutations are the basis of autosomal recessive familial pancreatitis.
Acute pancreatitis is a life-threatening disease. Once pancreatic self-digestion is triggered, the full cocktail of activated enzymes enters the circulation, activating inflammatory cells and damaging endothelial cells in distant organs. Potential outcomes include disseminated intravascular coagulation, hemolysis, shock, acute renal failure and acute respiratory distress syndrome (ARDS).
CYSTIC FIBROSIS
Cystic fibrosis is the most common life-threatening genetic disease in people of European origin, affecting about 1 in 2000. The autosomal recessive disease obtained its name from the destruction of pancreatic tissue, which originally resulted in severe malnutrition and early death due to the deficiency of pancreatic enzymes. Since the development of oral enzyme replacement, the major cause of morbidity is pulmonary disease. A thickened mucous layer inhibits ciliary clearance and forms an ideal substrate for infections with Pseudomonas aeruginosa and Staphylococcus aureus.
Cystic fibrosis is the result of mutations in the CF gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is required to produce the HCO 3 − -rich secretion of pancreatic fluid. While CFTR is a Cl --transporter at the apical membrane, ductal Cl − is required for exchange with HCO 3 − present within the ductal cell. CFTR consists of two membrane-spanning domains with adjacent ATP-binding sites, separated by a large regulatory cytoplasmic loop containing multiple PKA and PKC phosphorylation sites. Secretin action at the ductal cell activates PKA via cAMP, and parasympathetic stimulation by acetylcholine activates PKC. Thus, digestive stimuli activate HCO 3 − -rich secretion by phosphorylation of CFTR.
One mutation, ΔF508, causes about two thirds of all cases of CF. The deletion of phenylalanine 508 alters the structure of the protein in a way that it is broken down prematurely and does not reach the apical membrane. Many different other mutations, altogether more than 1000, each present in only a tiny fraction of patients, have been described to result in partial of total loss of CFTR function. CFTR is required in many epithelial cell types. Thus, its lack in CF patients may cause a host of medical problems, including meconium ileus in babies, sinusitis, infertility, diabetes and biliary cirrhosis.
Pharmacology cross reference:
In patients with a homozygous ΔF508 mutation, the combination of Lumacaftor/Ivacaftor (tablet, Orkambi®) is able to relieve symptoms: Lumacaftor has chaperone activity, so that a small proportion of CFTR proteins fold correctly and reach the membrane, where Ivacaftor increases open probability.
FAT DIGESTION is discussed in the lecture notes on liver pathphysiology.
SOME NON-INFECTIOUS INTESTINAL DISEASES

CELIAC DISEASE
Celiac disease, also known as gluten-sensitive enteropathy or celiac sprue, is an enteropathy triggered by certain proteins in wheat, rye or barley in genetically predisposed individuals. Oats are tolerated by most patients but tend to be cross-contaminated with other grains. Maize and rice are no problem. With a prevalence of 0.5 to 1%, celiac disease is quite common in Caucasians, while it is less frequent in other populations. Note that cereal grains entered human nutrition only 15,000 years ago.
Grain protein nomenclature is somewhat mystifying to non-experts. To enable germination, grains contain carbohydrates (in the form of starch) and amino acids (in the form of storage proteins). Starch and some of the proteins are water-soluble. The mix of non-water-soluble proteins is summarily called gluten (from the Latin word gluten, for glue). Generally, the alcohol-soluble subfraction of gluten proteins is called prolamins, as they are rich in prolines and glutamines. Prolamins have different names in specific grains. In wheat, these prolamins are called gliadins, in barley, hordeins and in rye, secalins. With wheat our predominant grain, gliadins, which come in several forms (α/β, γ and ω), usually are the pathogenic agents of celiac disease.
As our digestive proteases do not cleave peptide bonds next to prolines and glutamines efficiently, gliadins are resistant to enzymatic degradation in the intestine. The digestive process thus results in typical peptides of e. g., 20 -35 amino acids, which in sensitive persons are able to activate immune mechanisms in two ways.
Gliadin peptides have direct effects on enterocytes. Only a minority of these mechanisms are known in detail. Some of the gliadin peptides have an affinity to chemokine receptor CXCR3 on the apical membrane of enterocytes. Activation of CXCR3 results in secretion of the protein zonulin (pre-haptoglobin 2), which makes tight junctions more permeable, allowing gliadin peptides to cross the epithelial barrier. In addition, CXCR3-expressing lymphocytes may be attracted.
In addition, gliadin peptides cause enterocytes to secrete IL-15 and to express MICA, a MHC class I-like protein induced by various forms of cell stress, on their cell membrane. IL-15 causes intraepithelial lymphocytes to express the MICA-receptor NKG2D. Via this nonadaptive mechanism, the lymphocytes proceed to kill the epithelial cells, making the intestinal wall even more permeable and over time reducing the numbers of mature epithelial cells (villous atrophy).
In a second mechanism, the ubiquitously expressed enzyme tissue transglutaminase (tTG) converts glutamine residues to glutamic acid, and the resulting negatively charged gliadin fragments are preferentially presented in specific MHC II molecules, variants of HLA-DQ2 (heterodimers from DQA1*05 and DQB1*02 alleles) or HLA-DQ8 (heterodimers from DQA1*03 and DQB1*0302 alleles). Note that these are very common alleles, so their presence is in no way predictive of celiac disease, but other DQ-types seem unable to do the same job. Antigen-presenting cells (APC) presenting deamidated gliadin peptides on DQ activate naïve CD4-positive T cells. CD4+ T cells mainly differentiate into TH1 cells, which produce IFNγ. By activating macrophages and other cell types, this results in a chronic inflammatory state of the intestinal wall. As these mechanisms are cellular, they may be characterized as a type IV hypersensitivity reaction.
These mechanisms result in loss of mature enterocytes, which can be only insufficiently compensated by increased proliferation of transit amplifying cells in crypts. Accordingly, the diagnostic duodenal or jejunal biopsy shows villous atrophy, crypt hyperplasia and an increase in intraepithelial lymphocytes.
Before biopsy, useful serologic tests include IgA antibodies against tissue transglutaminase and antibodies against deamidated gliadin. Antibodies are a byproduct, rather than a disease mechanism. Usually, tTG-specific T helper cells are not found, and should not be found, as tTG is a self-molecule. The antibodies are generated when B cells expressing a tTG-binding B cell receptor internalize a complex of tTG attached to a gliadin peptide. Presenting the gliadin peptide on MHC DQ, the B cell gets help from a gliadin-specific T cell to produce a tTGspecific autoantibody.
Celiac disease may start at any age and at any intensity, with many atypical presentations. The lack of mature enterocytes leads to nutritional deficits, e. g., regarding iron and vitamins. In a full-fledged form, symptoms may include abdominal distention, chronic diarrhea, weight loss or failure to thrive.
The only effective treatment is a life-long gluten-free diet.
INFLAMMATORY BOWEL DISEASE
Inappropriate immune activation in the intestinal mucosa is the hallmark of inflammatory bowel disease (IBD), which comprises Crohn's disease and ulcerative colitis. While showing many similarities, the two diseases differ in affected sites and in the depth of penetration of the inflammatory process. Ulcerative colitis is limited to the colon and rectum, and affects only mucosa and submucosa; perforations are rare. Crohn's disease, in contrast, may affect any part of the gastrointestinal tract. Frequently, it involves several intestinal segments at the same time, e.g., terminal ileum and rectum, in an inflammatory process that is typically transmural.
Inflammatory bowel syndrome seems to involve an aberrant immune response against intestinal microbiota. In this sense, it is not an autoimmune disease, which would require a self-antigen. On the other hand, we could also regard our gut microbiota as part of our "greater self", as we are tolerized against it under normal circumstances. In IBD, something in this tolerization progress has gone wrong. This seems to be facilitated by certain alleles of polymorphic loci. In many IBD patients, the epithelial barrier seems to be weakened. In a connection that is not yet sufficiently understood, tight junctions between epithelial cells are more permeable in patients with specific NOD2 alleles. Recall that NOD2 is an intracellular pattern recognition receptor for PAMPs from bacterial cell walls. Another group of patients seem to produce lower amounts of defensins, anti-bacterial peptides secreted into the intestinal lumen by, e. g., cryptal Paneth cells. In summary, several polymorphic loci may contribute to the fact that more bacterial material than normal permeates the intestinal wall.
Reacting to these bacterial components, dendritic cells activate naïve T cells to become TH17 and TH1 cells. Recall that TH17 cells enhance early non-specific immune mechanisms, especially recruitment of neutrophils. Abundant neutrophils are typical for IBD, infiltrating and destroying crypts in the form of crypt abscesses. Macrophages are activated directly by bacterial PAMPs, as well as by TH1 cells via IFNγ. TNFα secreted by macrophages and TH1 cells contributes to tissue damage via protease induction, and proteases in turn damage tight junctions. In summary, innate and adaptive immune mechanisms increase epithelial permeability in a vicious circle.
Pharmacology cross reference:
Anti-TNFα therapy is beneficial in treating fistulating Crohn's disease.
Environmental factors have an influence, too. Populations less exposed to certain infectious diseases have been found to suffer more from IBD, a phenomenon also observed with respect to allergic diseases. The hygiene hypothesis postulates a requirement for infections to establish normal tolerance levels. In animal models, helminth infection is able to prevent or reduce IBD development. Compatible with this hypothesis, IBD incidence worldwide is on the rise, and prevalence in Europe, North America and Australia is higher than in other parts of the world.
Hyper reaction from the immune system is also seen in extra-intestinal manifestations, including erythema nod sum, migratory polyarthritis, sacroileitis, ankylosing spondylitis, uveitis and cholangitis.
Symptoms vary widely, depending on location and intensity. Crohn's disease begins in most patients with moderate diarrhea, abdominal pain and fever, sometimes mimicking acute appendicitis. Colitis ulcerosa, with its involvement of distal colon and rectum, typically comes with lower abdominal cramps and diarrhea with bloody and mucous constituents. In both forms, the disease tends to be chronic, starting at a young age, with attacks that come and go, and may require surgery. ***
